Truist Maintains Buy Rating on Intuitive Surgical (ISRG)
Truist has maintained a Buy rating on Intuitive Surgical (ISRG) despite lowering its price target to $580 from $650. The firm expects the company's first-quarter performance to meet or exceed expectations, citing sustained procedure growth and a new product cycle. However, the FDA is investigating a safety issue with Intuitive Surgical's staplers, which has raised concerns.
Tickers: $ISRG
Topics: analyst report FDA safety issue medical devices price target stock rating